Shares of Cell MedX Corp. (OTCMKTS:CMXC – Get Free Report) dropped 29.1% on Thursday . The stock traded as low as $0.2611 and last traded at $0.2611. Approximately 300 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 20,342 shares. The stock had previously closed at $0.3684.
Cell MedX Price Performance
The stock’s 50-day moving average is $0.38 and its 200-day moving average is $0.35.
About Cell MedX
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.
Further Reading
- Five stocks we like better than Cell MedX
- Top Biotech Stocks: Exploring Innovation Opportunities
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Cell MedX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell MedX and related companies with MarketBeat.com's FREE daily email newsletter.
